United States
Rapport Therapeutics, founded in 2022, is a pioneering company in the Biotechnology, Health Care, and Life Sciences industries. It is based in the United States, specifically in San Diego, CA and Boston, MA. The company is devoted to transforming neurological disorder treatments through precision medicine, aiming to match the complexity of the human brain by targeting disease-driving neurocircuits with receptor-associated proteins (RAPs). This innovative approach promises to enhance efficacy and reduce side effects compared to traditional neuromedicines.
Launched in March 2023, Rapport is backed by a formidable team of neuroscience and drug discovery experts. It emerged from a collaboration between Third Rock Ventures and Johnson & Johnson Innovation-JJDC, Inc. The company recently secured a $150.00M Series B investment on 23 August 2023, attracting investors such as Arch Venture Partners, Sofinnova Investments, and Goldman Sachs Asset Management, among others.
